To analyze whether targeting the RAR-PRAME-EZH2 axis has anti-tumor activity, we assessed cell proliferation in SYO-1, MoJo, and HSSY-II (TP-SS) and SW982 (TN-SS) cells following single treatment with GSK343 or ATRA, and in combination for seven days. The gene discussed is EZH2; the disease is neoplasm.